Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Total Liabilities (2016 - 2025)

Sutro Biopharma (STRO) has disclosed Total Liabilities for 10 consecutive years, with $306.3 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 10.6% to $306.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $306.3 million through Dec 2025, down 10.6% year-over-year, with the annual reading at $306.3 million for FY2025, 10.6% down from the prior year.
  • Total Liabilities hit $306.3 million in Q4 2025 for Sutro Biopharma, up from $296.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $347.2 million in Q1 2025 to a low of $51.2 million in Q1 2021.
  • Historically, Total Liabilities has averaged $229.7 million across 5 years, with a median of $295.7 million in 2025.
  • Biggest five-year swings in Total Liabilities: dropped 28.69% in 2021 and later soared 237.67% in 2022.
  • Year by year, Total Liabilities stood at $88.8 million in 2021, then soared by 113.74% to $189.9 million in 2022, then surged by 69.09% to $321.1 million in 2023, then rose by 6.7% to $342.6 million in 2024, then fell by 10.6% to $306.3 million in 2025.
  • Business Quant data shows Total Liabilities for STRO at $306.3 million in Q4 2025, $296.9 million in Q3 2025, and $294.5 million in Q2 2025.